These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19476859)

  • 21. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
    Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
    Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
    Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
    Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications.
    Glaser RL; York AE; Dimitrakakis C
    Menopause; 2017 Jul; 24(7):859-864. PubMed ID: 28195993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017.
    McGuire KP; Hwang ES; Cantor A; Golshan M; Meric-Bernstam F; Horton JK; Nanda R; Amos KD; Forero A; Hudis CA; Meszoely I; De Los Santos JF
    Ann Surg Oncol; 2015 Jan; 22(1):75-81. PubMed ID: 25059792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
    Skriver SK; Jensen MB; Knoop AS; Ejlertsen B; Laenkholm AV
    Breast Cancer Res; 2020 May; 22(1):46. PubMed ID: 32410705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?
    Jochelson MS; Lampen-Sachar K; Gibbons G; Dang C; Lake D; Morris EA; Morrow M
    Ann Surg Oncol; 2015 May; 22(5):1490-5. PubMed ID: 25777093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of Neoadjuvant Chemotherapy on Margin Re-excision in Breast-Conserving Surgery.
    Devane LA; Baban CK; O'Doherty A; Quinn C; McDermott EW; Prichard RS
    World J Surg; 2020 May; 44(5):1547-1551. PubMed ID: 32002582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for Mastectomy after Neoadjuvant Chemotherapy.
    Gusic LH; Walsh K; Flippo-Morton T; Sarantou T; Boselli D; White RL
    Am Surg; 2018 Jan; 84(1):126-132. PubMed ID: 29428039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
    Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; van den Bosch J; Maartense E; van Leeuwen-Stok AE; Liefers GJ; Nortier JWR; Rutgers EJT; van de Velde CJH;
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
    Colleoni M; Luo W; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Hitre E; Graas MP; Simoncini E; Kamby C; Thompson A; Loibl S; Gavilá J; Kuroi K; Marth C; Müller B; O'Reilly S; Di Lauro V; Gombos A; Ruhstaller T; Burstein H; Ribi K; Bernhard J; Viale G; Maibach R; Rabaglio-Poretti M; Gelber RD; Coates AS; Di Leo A; Regan MM; Goldhirsch A;
    Lancet Oncol; 2018 Jan; 19(1):127-138. PubMed ID: 29158011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
    Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
    Mamounas EP
    Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
    Allevi G; Strina C; Andreis D; Zanoni V; Bazzola L; Bonardi S; Foroni C; Milani M; Cappelletti MR; Gussago F; Aguggini S; Giardini R; Martinotti M; Fox SB; Harris AL; Bottini A; Berruti A; Generali D
    Br J Cancer; 2013 Apr; 108(8):1587-92. PubMed ID: 23579222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
    Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
    Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.